Acute myocardial infarction soon after nicotine replacement therapy

Mathew, T. P.; Herity, Niall A.

doi:10.1093/qjmed/94.9.503

Cited by 15 publications

(18 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Anecdotally, adverse CVD events, including acute myocardial infarction (MI), coronary vasospasm, aortic dissection, vasculitis, intracranial vasospasm, and intracerebral hemorrhage, have been demonstrated in patients with NRT [25][26][27][28][29][30][31][32]. It is important to keep in mind that smokers, irrespective of NRT usage, have an increased risk for all CVD events compared with nonsmokers [1,4].…”

Section: Nicotine Replacement Therapymentioning

confidence: 99%

“…A recent network meta-analysis of 21 RCTs involving NRT [40••] demonstrated a statistically significant association of lower-risk events like arrhythmia and tachycardia with the use of NRT, which are well-documented benign side effects [25,28,32,35]. These occurred primarily in studies with longer periods of follow-up.…”

Section: Nrt In Smokers With Known Cvdmentioning

confidence: 99%

“…There are several hypotheses as to why NRT use may increase CVD events, although not well understood [25,28,32,35]. Smokers very well might have established CAD due to long-standing history of smoking.…”

Section: Nrt In Smokers With Known Cvdmentioning

confidence: 99%

“…Smokers very well might have established CAD due to long-standing history of smoking. Also, in smokers with unstable CAD, coronary vasoconstriction associated with plaque rupture due to quitting and arrhythmia risk associated with NRT may increase the risk of acute coronary syndrome [32]. In patients who continue to smoke after receiving NRT, increase in blood pressure, stroke volume, and cardiac output are observed due to stimulation of sympathetic nervous system [32].…”

Section: Nrt In Smokers With Known Cvdmentioning

confidence: 99%

“…Also, in smokers with unstable CAD, coronary vasoconstriction associated with plaque rupture due to quitting and arrhythmia risk associated with NRT may increase the risk of acute coronary syndrome [32]. In patients who continue to smoke after receiving NRT, increase in blood pressure, stroke volume, and cardiac output are observed due to stimulation of sympathetic nervous system [32]. However, patients on placebo who continued to smoke had increased CVD events than those on a nicotine patch [34].…”

Section: Nrt In Smokers With Known Cvdmentioning

confidence: 99%

See 4 more Smart Citations

Cardiovascular Adverse Events Associated with Smoking-Cessation Pharmacotherapies

et al. 2014

View full text Add to dashboard Cite

Smoking continues to be the leading cause of preventable deaths in the USA, accounting for one in every five deaths every year, and cardiovascular (CV) disease remains the leading cause of those deaths. Hence, there is increasing awareness to quit smoking among the public and counseling plays an important role in smoking cessation. There are different pharmacological methods to help quit smoking that includes nicotine replacement products available over the counter, including patch, gum, and lozenges, to prescription medications, such as bupropion and varenicline. There have been reports of both nonserious and serious adverse CV events associated with the use of these different pharmacological methods, especially varenicline, which has been gaining media attention recently. Therefore, we systematically reviewed the various pharmacotherapies used in smoking cessation and analyzed the evidence behind these CV events reported with these therapeutic agents.

show abstract

Section: Nicotine Replacement Therapymentioning

confidence: 99%

Section: Nrt In Smokers With Known Cvdmentioning

confidence: 99%

Section: Nrt In Smokers With Known Cvdmentioning

confidence: 99%

Section: Nrt In Smokers With Known Cvdmentioning

confidence: 99%

Section: Nrt In Smokers With Known Cvdmentioning

confidence: 99%

See 3 more Smart Citations

Cardiovascular Adverse Events Associated with Smoking-Cessation Pharmacotherapies

et al. 2014

View full text Add to dashboard Cite

show abstract

Paroxysmal Atrial Fibrillation After Smokeless Tobacco (Maras Powder) Use

Söğüt

Sayhan

Üstündağ

et al. 2009

Journal of the Chinese Medical Association

View full text Add to dashboard Cite

Use of cigarettes and smokeless tobacco is a considerable public health problem. In Turkey, a type of smokeless tobacco called Maras powder (MP) is widely used in the Southeastern region. We present a case of paroxysmal atrial fibrillation that was suspected to be caused by the use of MP, which has never previously been noted in the literature. A 46-year-old man was admitted to our emergency department with angina pectoris and palpitation. He was a long time cigarette smoker and had begun using MP the fortnight before. Electrocardiography showed atrial fibrillation with rapid ventricular response. The patient had no medical history of alcohol use, surgery, palpitation, coronary arterial illness, hypertension or chronic bronchitis. Atrial fibrillation was converted to sinus rhythm after antiarrhythmic medication. Our patient was discharged from the emergency department with a suggestion to quit MP usage immediately. In conclusion, the use of MP may lead to the occurrence of paroxysmal atrial fibrillation.

show abstract

Safety issues in pharmacotherapy for smoking in patients with cardiovascular disease

Joseph

2003

Progress in Cardiovascular Diseases

View full text Add to dashboard Cite

Acute myocardial infarction soon after nicotine replacement therapy

Cited by 15 publications

References 6 publications

Cardiovascular Adverse Events Associated with Smoking-Cessation Pharmacotherapies

Cardiovascular Adverse Events Associated with Smoking-Cessation Pharmacotherapies

Paroxysmal Atrial Fibrillation After Smokeless Tobacco (Maras Powder) Use

Safety issues in pharmacotherapy for smoking in patients with cardiovascular disease

Contact Info

Product

Resources

About